In the UK we have a saying that you wait hours for a bus and then two come along at once. Well, it seems that in this case FRAILOMIC newsletters are like buses! We have another update on the Frailomic consortium following on quickly from our previous on in December. You can download the latest issue [1].
In the current issue we report on the annual 2-day Frailomic gathering that was held in Mallorca last November. The meeting served as an opportunity for the consortium partners to update each other on the project’s achievements and advances. The exploratory phase of the study was designed to ensure that all biological samples from each cohort were delivered successfully to the laboratories involved. These samples have been received and processed over the course of the last year, and this phase should be completed by the end of this month. The second phase of Frailomic, the validation phase, will include cohorts from ENRICA, SARDINIA, MAPT, SAGE and COURAGE (WHO cohorts), and ETES. A meeting will be arranged in January 2015 to consider key information regarding each cohort (for example, types of clinical and biological information available, types and amounts of samples available, and any legal or ethical issues that are specific to any cohort). Full information is provided on the study website [2].
Day 1 was mostly taken up with partner organisations reporting on progress they have made on analysing the samples. Emphasis on Day 2 was placed on discussion of the various study cohorts and the approach to the statistical analysis. The Niche team reported on how the first manuscript in the Frailomic publication plan had been submitted to the journal Gerontology and it was decided during the meeting that the second and third manuscripts would be combined into a single submission.
References
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
